Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) has completed internal validation of a proprietary quantum sampling workflow within its clinical trials data analysis Platform. The workflow allows continuous probability distributions to be represented and analyzed in a quantum computing framework using a major S&P 500 company’s hybrid quantum-classical platform.
According to SciSparc, the validated workflow underpins a key part of the Platform’s computational architecture and is expected to expand capabilities for large-scale clinical and biomedical datasets. The methodology converts continuous data into quantum-operable energy landscapes, enabling Quantum Markov Chain Monte Carlo (QMCMC) sampling while preserving original statistical properties. Quantum dynamics generate proposals and classical logic enforces the target distribution, maintaining statistical guarantees. The Platform is advanced via CliniQuantum, a quantum-focused initiative in which NeuroThera holds 54.01%.
SciSparc (Nasdaq: SPRC) announced that its board of directors has decided to target the agentic artificial intelligence market. As part of this strategic move, SciSparc will establish a Scientific Advisory Board focused on AI and cybersecurity and is evaluating opportunities through discussions with several agentic AI companies.
SciSparc (Nasdaq: SPRC) announced that subsidiary NeuroThera Labs (TSXV: NTLX) has initiated a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a proprietary cannabinoid-based candidate for treating Tourette Syndrome (TS) in adults.
The trial, previously cleared by Germany’s Federal Institute for Drugs and Medical Devices and MHH’s ethics committee, is a randomized, double-blind, placebo-controlled, cross-over study assessing daily oral SCI-110. It will also enroll at Yale Child Study Center in the US and Tel Aviv Sourasky Medical Center in Israel. According to SciSparc, the Phase IIa study showed an average 21% tic reduction on the Yale Global Tic Severity Scale, and Phase IIb will evaluate efficacy, safety, and tolerability in adults aged 18–65, using tic severity change at weeks 12 and 26 as the primary endpoint.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) closed the acquisition of approximately 54% of CliniQuantum by issuing 56,600,000 NeuroThera common shares, valued at about CAD$9.46 million.
Selling shareholders may receive up to US$2.5 million in earn-outs over three years. CliniQuantum holds a key license from Quantum X Labs for quantum simulation and quantum Monte Carlo methods in clinical trials. An SPA amendment set a CAD$0.05 floor price for future earn-out share issuances and added lock-up arrangements.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) received conditional TSX Venture Exchange approval to acquire approximately 54% of CliniQuantum.
The deal involves issuing 56,600,000 NeuroThera shares, valued at about $9.46 million, escrowed under TSX policies, with amended SPA terms including a $0.05 floor price for earn-out shares and an extended outside closing date to June 1, 2026.
SciSparc (Nasdaq: SPRC) announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, is collaborating with Clearmind Medicine on a patent application filed in Hong Kong for a novel MEAI‑PEA combination therapy aimed at treating major depressive disorder.
The filing describes a non‑hallucinogenic neuroplastogen approach combining Clearmind’s MEAI with Palmitoylethanolamide (PEA) sourced by NeuroThera. According to the filing context, the therapy targets depression, which affects > 332 million people worldwide per WHO (Aug 2025).
SciSparc (Nasdaq: SPRC) said NeuroThera Labs (TSXV: NTLX), in which SciSparc holds a controlling interest of ~75%, advanced a collaboration with Clearmind via publication of a PCT international patent application for a MEAI–PEA combination targeting weight loss and MASLD.
The release cites global prevalence figures (obesity ~890 million adults; MASLD ~30% adults) and market estimates (weight loss drugs ~$37B in 2025, ~$226B by 2035).
SciSparc (Nasdaq: SPRC) announced that its majority-controlled subsidiary NeuroThera Labs (TSXV: NTLX) signed a definitive share purchase agreement to acquire approximately 54.01% of CliniQuantum (CliniQ), a quantum‑technology company focused on quantum simulation for clinical trials.
NeuroThera will issue 56,600,000 common shares valued at about $9,459,954.20 and may pay up to $2,500,000 in earn-outs over three years. Closing is expected on or about March 31, 2026, subject to conditions including an Israeli tax ruling.
SciSparc (Nasdaq: SPRC) will effect a 1-for-9 reverse share split effective at market open on March 4, 2026, reducing issued and outstanding ordinary shares from 5,089,501 to approximately 565,500.
The Ordinary Shares will continue trading under the symbol SPRC on Nasdaq on a split-adjusted basis and will receive a new CUSIP: M82618139. The split was approved June 26, 2025; authorized share capital remains 2,000,000,000 Ordinary Shares. Fractional shares will be rounded at the DTC participant level; options and warrants will be adjusted proportionately.
SciSparc (Nasdaq: SPRC) announced on Feb 2, 2026 that NeuroThera Labs was granted a U.S. patent for a proprietary combination of antimicrobials and cannabinoids designed to potentiate antibiotics versus resistant Gram-positive pathogens such as MRSA.
The patent joins prior U.S. and European grants, is based on preclinical data, and targets a global antibiotics market projected near $58 billion in 2026. SciSparc holds an approximate 75% controlling interest in NeuroThera.